Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On March 10, 2017, Endocyte, Inc. (the “Company”) announced its results of operations for the three months and full year ended December 31, 2016. A copy of the Company’s earnings release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

On March 10, 2017, the Company issued a press release announcing its plan to collaborate with Seattle Children’s Research Institute and Dr. Michael Jensen for the development of Endocyte’s SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte’s proprietary SMDC bi-specific adaptor molecules. A copy of the Company’s press release is furnished herewith as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d)         Exhibits

99.1       Earnings Release dated March 10, 2017 

99.2       Press Release dated March 10, 2017

The information in this Current Report (including Exhibit 99.1 and Exhibit 99.2) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1 and Exhibit 99.2) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.


About Endocyte, Inc.  (NASDAQ:ECYT)

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Endocyte, Inc.  (NASDAQ:ECYT) Recent Trading Information

Endocyte, Inc.  (NASDAQ:ECYT) closed its last trading session 00.00 at 2.27 with 254,886 shares trading hands.